The purpose of this study is to determine if experimental drug treatment improves recovery after TBI as compared to a control (placebo) group. Changes in recovery will be measured throughout the study. The study drugs listed below are approved by the U.S. Food and Drug Administration (FDA) but are being used "off-label" in this study. This means that the drugs are not currently approved to treat TBI.

Start Date01 Aug 2024

Sponsor / Collaborator

The University of California, San Francisco

[+1]

CTR20240847 / CompletedNot Applicable

坎地沙坦酯片在健康受试者中餐后状态下随机、开放、单剂量、两制剂、两周期、两序列、自身交叉的生物等效性试验

[Translation] A randomized, open-label, single-dose, two-formulation, two-period, two-sequence, self-crossover bioequivalence study of candesartan cilexetil tablets in healthy volunteers in the postprandial state

主要目的：以珠海润都制药股份有限公司生产的坎地沙坦酯片（规格：16mg）为受试制剂，以ANI Pharmaceuticals, Inc.持证的坎地沙坦酯片（商品名：Atacand®，规格：16mg）为参比制剂，在餐后状态下考察两制剂在健康受试者中的生物等效性。次要目的：观察受试制剂坎地沙坦酯片和参比制剂坎地沙坦酯片（Atacand®）在健康受试者中的安全性。

[Translation]

Primary objective: To investigate the bioequivalence of the two preparations in healthy subjects in the postprandial state, using Candesartan Cilexetil Tablets (specification: 16 mg) produced by Zhuhai Rundu Pharmaceutical Co., Ltd. as the test preparation and Candesartan Cilexetil Tablets (trade name: Atacand®, specification: 16 mg) certified by ANI Pharmaceuticals, Inc. as the reference preparation. Secondary objective: To observe the safety of the test preparation Candesartan Cilexetil Tablets and the reference preparation Candesartan Cilexetil Tablets (Atacand®) in healthy subjects.

Start Date18 Mar 2024

Sponsor / Collaborator

Zhuhai Rundu Pharmaceutical Co., Ltd.

CTR20240344 / CompletedNot Applicable

坎地沙坦酯片在健康受试者中空腹状态下随机、开放、单剂量、两制剂、两周期、两序列、自身交叉的生物等效性试验

主要目的：以珠海润都制药股份有限公司生产的坎地沙坦酯片（规格：16mg）为受试制剂，以ANI Pharmaceuticals, Inc.持证的坎地沙坦酯片（商品名：Atacand®，规格：16mg）为参比制剂，在空腹状态下考察两制剂在健康受试者中的生物等效性。次要目的：观察受试制剂坎地沙坦酯片和参比制剂坎地沙坦酯片（Atacand®）在健康受试者中的安全性。

[Translation]

Primary objective: To investigate the bioequivalence of the two preparations in healthy subjects under fasting state, using Candesartan Cilexetil Tablets (specification: 16 mg) produced by Zhuhai Rundu Pharmaceutical Co., Ltd. as the test preparation and Candesartan Cilexetil Tablets (trade name: Atacand®, specification: 16 mg) certified by ANI Pharmaceuticals, Inc. as the reference preparation. Secondary objective: To observe the safety of the test preparation Candesartan Cilexetil Tablets and the reference preparation Candesartan Cilexetil Tablets (Atacand®) in healthy subjects.

Start Date25 Jan 2024

Sponsor / Collaborator

Zhuhai Rundu Pharmaceutical Co., Ltd.

100 Clinical Results associated with Candesartan Cilexetil

100 Translational Medicine associated with Candesartan Cilexetil

100 Patents (Medical) associated with Candesartan Cilexetil

3,257

Literatures (Medical) associated with Candesartan Cilexetil

31 Dec 2024·Clinical and experimental hypertension (New York, N.Y. : 1993)

Chronic exercise improves renal AT ₁ and ETB receptor functions via modulating GRK4 expression in obese Zucker rats

Article

Author: Li, Zhengsheng ; Lu, Jingjing ; Yang, Yinan ; Wei, Fangning

BACKGROUND:

Physical activity has profound benefits on health, especially in patients with cardiovascular and metabolic disease. Exercise training can reduce oxidative stress, improve renal function, and thus lower blood pressure. However, the effect of exercise training on angiotensin II type 1 receptors (AT₁R) and endothelin subtype B receptors (ETBR)-mediated diuresis and natriuresis in obese Zucker rats is unclear.

METHODS:

Lean and obese Zucker rats were exercised or placed on a nonmoving treadmill for 8 weeks. Blood pressure was measured by tail-cuff plethysmography, and functions of AT₁R and ETBR in the kidney were measured by natriuresis, respectively.

RESULTS:

Our data showed that exercise training improved glucose and lipid metabolism, renal function and sodium excretion in obese Zucker rats, accompanied by decreased oxidative stress and GRK4 expression in obese Zucker rats. Moreover, exercise training reduced the Candesartan-induced an increase in diuresis and natriuresis and increased ETBR agonists (BQ3020)-mediated diuresis and natriuresis in obese Zucker rats, which were associated with decreased renal AT₁R expression and ETBR phosphorylation levels.

CONCLUSIONS:

The results demonstrate that exercise training lowers blood pressure via improving renal AT₁R and ETBR function through modulating GRK4 expression in Obese Zucker Rats and provides potentially effective targets for obesity-related hypertension.

31 Dec 2024·BLOOD PRESSURE

Guidelines-based therapeutic strategies for controlling hypertension in non-controlled hypertensive patients followed by family physicians in primary health care in Portugal: the GPHT-PT study

Article

Author: Marques Pereira, Raul ; Polónia, Jorge

PURPOSE:

In a prospective open study, with intervention, conducted in Primary Health Care Units by General Practitioners (GPs) in Portugal, the effectiveness of a single pill of candesartan/amlodipine (ARB/amlodipine), as the only anti-hypertension (anti-HTN) medication, in adult patients with uncontrolled HTN (BP > 140/or > 90 mm Hg), either previously being treated with anti-HTN monotherapies (Group I), or combinations with hydrochlorothiazide (HCTZ) (Group II), or not receiving medication at all (Group III), was evaluated across 12-weeks after implementation of the new therapeutic measure.

MATERIALS AND METHODS:

A total of 118 GPs recruited patients with uncontrolled HTN who met inclusion/exclusion criteria. Participants were assigned, according to severity, one of 3 (morning) fixed combination candesartan/amlodipine dosage (8/5 or 16/5 or 16/10 mg/day) and longitudinally evaluated in 3 visits (v0, v6 and v12 weeks). Office blood pressure was measured in each visit, and control of HTN was defined per guidelines (BP< 140/90 mmHg).

RESULTS:

Of the 1234 patients approached, 752 (age 61 ± 10 years, 52% women) participated in the study and were assigned to groups according to previous treatment conditions. The 3 groups exhibited a statistically significant increased control of blood pressure after receiving the fixed combination candesartan/amlodipine dosage. The overall proportion of controlled HTN participants increased from 0,8% at v0 to 82% at v12. The mean arterial blood pressure values decreased from SBP= 159.0 (± 13.0) and DBP= 91.1 (± 9.6) at baseline to SBP= 132,1 (± 11.3) and DBP= 77,5 (± 8.8) at 12 weeks (p < 0.01). Results remained consistent when controlling for age and sex.

CONCLUSION:

In patients with uncontrolled HTN, therapeutic measures in accordance with guidelines, with a fixed combination candesartan/amlodipine, allowed to overall achieve HTN control at 12 weeks in 82% of previously uncontrolled HTN patients, reinforcing the advantages of these strategies in primary clinical practice.

01 Dec 2024·ADVANCES IN THERAPY

A Systematic Literature Review and Network Meta-analysis of Azilsartan Medoxomil Compared to Other Anti-hypertensives Efficacy in Lowering Blood Pressure Amongst Mild to Moderate Hypertensive Patients

Review

Author: Chen, Zhangwei ; Zhang, Mengjun ; Qian, Juying

INTRODUCTION:

A systematic literature review and network meta-analysis was conducted on azilsartan medoxomil (AZL-M) versus other antihypertensive drugs' efficacy in hypertensive patients.

METHODS:

The search utilized English platforms, from January 2000 until December 2023, resulting in 10,380 articles being screened. Screening criteria included hypertension (mild or moderate); first-line treatment and washout periods; studies (monotherapy) with AZL-M, angiotensin type II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor neprilysin inhibitor (ARNIs), beta-blockers, calcium channel blockers (CCBs), and diuretics, either as intervention or comparator; and antihypertension efficacy as an outcome measure. Study design was randomized clinical trials. Efficacy variables included absolute office systolic and diastolic blood pressure (BP) reductions. A total of 21 publications provided adequate data for analysis, of which 20 studies reported both systolic and diastolic BP and one study reported only the diastolic BP.

RESULTS:

In 21 studies on systolic BP, against the common comparator placebo, the differences in systolic BP were significantly in favor of AZL-M, amlodipine, candesartan, irbesartan, nebivolol, nifedipine, olmesartan, sacubitril valsartan, telmisartan, and valsartan. The surface under the cumulative ranking curve (SUCRA) ranking shows that AZL-M 80 mg had the highest ranking, with a possibility of 93% being the best in all other included treatments. In 20 studies on diastolic BP, against the common comparator placebo, the differences in diastolic BP were significantly in favor of AZL-M, amlodipine, bisoprolol, nebivolol, olmesartan, sacubitril valsartan, telmisartan, and valsartan. The SUCRA ranking shows that AZL-M 80 mg had the highest ranking, with a possibility of 90% being the best in all other included treatments.

CONCLUSION:

AZL-M at 40 mg and 80 mg shows favorable efficacy compared to other anti-hypertensives, and the 80 mg dosage seemed to be the most efficacious of all the included treatments in reducing both office systolic and diastolic BP in patients with mild-to-moderate hypertension.

News (Medical) associated with Candesartan Cilexetil

09 Aug 2023

·www.prnewswire.com

China Pharma's Candesartan Hypertension Product Passes the Quality and Efficacy Consistency Evaluation of Generic Drugs

HAIKOU, China, Aug. 9, 2023 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that its wholly-owned subsidiary Hainan Helpson Medical & Biotechnology Co., Ltd. (hereinafter referred to as "Helpson") has received the "Drug Supplementary Application Approval Notice" for its candesartan tablets by National Medical Products Administration of China (hereinafter referred to as NMPA"), indicating that the Company's candesartan tablets have passed the quality and efficacy consistency evaluation of generic drugs. The consistency evaluation of generic drugs evaluates approved generic drugs based on the principle that generic drugs need to reach the same level of quality and efficacy as the innovator drug, and can replace the innovator drug in clinical practice. This not only saves medical expenses, but also ensures the safety and effectiveness of public medication. Candesartan is an angiotensin II antagonist (ARB), suitable for primary hypertension, and is the smallest dose of sartan drugs. The dosage is 4-16mg, once a day. It is the most stable and strongest receptor binding sartan drug. It is tightly bound to four sites of AT1 receptor, with high affinity and slow dissociation characteristics. It is used to maintain stable blood pressure control for 24 hours; reduce the risk of morning spikes caused by blood pressure fluctuations; reduce target organ damage caused by blood pressure fluctuations; help to reduce the hospitalization risk and mortality rate of patients with chronic heart failure, and improve symptoms and exercise ability. According to the 2023 edition of the China Cardiovascular Disease Report compiled by the National Center for Cardiovascular Disease in China, there are currently 290 million cardiovascular disease patients in China, including 270 million hypertensive patients. According to data from Mi Nei Net, the sales of candesartan tablets in urban, county-level public hospitals, and urban retail pharmacies in China in 2021 were RMB226 million (USD$35 million) and RMB173 million (USD$27 million), respectively. Ms. Zhilin Li, China Pharma's Chairman and CEO, commented, "Candesartan tablets have long been one of our flagship products. We are excited that it passed generic-drug-consistency-evaluation. Such achievement not only shows that the quality and efficacy of our Candesartan have been recognized by the NMPA, indicating its ability to replace the innovator drug in clinical practice, but also signifies that it has the qualification to participate in China's national centralized procurement, which will greatly enhance our competitiveness in the field of government procurement." About China Pharma Holdings, Inc. China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit . The Company routinely posts important information on its website. Safe Harbor Statement Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations, except as required by applicable law or regulation. For more information, please contact Investor Relations: China Pharma Holdings, Inc. Ms. Diana Na Huang Phone: +86-898-6681-1730 (China) Email: [email protected] SOURCE China Pharma Holdings, Inc.

Drug Approval

01 Nov 2021

·endpts.com

AstraZeneca sells two COPD drugs to a familiar partner as Pascal Soriot's oncology push marches on

As CEO Pascal Soriot continues his long-running pivot toward oncology, AstraZeneca is offloading another pair of respiratory drugs. The drugmaker is selling off two medicines containing the active ingredient aclidinium bromide to Covis Pharma Group, the companies announced Monday morning, and receiving $270 million in return. Covis will also cover ongoing development costs for the drugs, which are marketed as Tudorza and Duaklir in the US. Both medicines treat chronic obstructive pulmonary disease and are delivered using the same device. Tudorza was first approved by the FDA in 2012 and Duaklir in 2019. The meds brought in a combined $143 million in sales last year, AstraZeneca said. Soriot has made oncology AstraZeneca’s new R&D mission as his company continues to push high-profile cancer drugs such as Tagrisso and Imfinzi. The former is AstraZeneca’s best-selling blockbuster, having brought in nearly $2.5 billion in sales in the first half of 2021. Imfinzi didn’t do too bad itself, however, bringing in $1.16 billion. But such an evolution ostensibly requires some small sacrifices, as Soriot has engaged in numerous divestitures in recent years. Most notably, AstraZeneca bid farewell to its one-time megablockbuster Crestor last December, selling rights to German firm Grünenthal for $320 million upfront and $30 million in milestones. That price couldn’t hold a candle to the drug’s former peak sales, when Crestor tallied $6.6 billion in 2011 and $5 billion as recently as 2015. But generics had sharply cut into Crestor sales by 2016, with AstraZeneca failing to block FDA approval in a last-ditch court effort. AstraZeneca had also sold two heart failure and hypertension drugs, Atacand and Atacand Plus, to Cheplapharm for $400 million in October 2020. AstraZeneca’s patents for the drugs in Monday’s deal don’t expire until 2029, according to a public records search of the FDA’s Orange Book, but it’s not clear when their market exclusivity ends. It’s also not the first time Covis has acquired drugs from the big British-Swedish pharma company. In November 2018, AstraZeneca gave Covis global rights to three respiratory drugs for $350 million after selling US rights a year earlier. The drugs were Alvesco, a maintenance therapy for asthma, and Omnaris and Zetonna, nasal sprays for seasonal and perennial rhinitis. The moves fit into Covis’ larger strategy of acquiring several brand name and generic drugs from major biopharmas, as the Swiss firm now says it’s a top 10 global respiratory company. Though the earlier AstraZeneca deal had brought Covis’ only such drugs before Monday’s deal, its portfolio also includes the heartburn drug Prilosec, the cholesterol med Altoprev and the ALS generic drug riluzole.

Generic Drug

23 Dec 2020

·www.geneonline.com

China’s Hasten Biopharmaceutic Acquires Five Non-Core Assets from Japan’s Takeda

Continuing its divestiture strategy since January 2019, Takeda has planned on releasing non-core assets to focus on creating innovative therapies and developments on Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies, Oncology, and Neuroscience, the 5 chosen areas that are essential to its long-term growth strategy. After the divestiture with Celltrion in early December, Takeda struck up another deal with Hasten Biopharmaceutic, a company funded by Feidong County of Hefei City, China and established by Ray Capital Management Limited. Takeda is letting go of five prescription drugs, including cardiovascular and metabolism products that are mainly sold in China in exchange for around 322 million. The portfolio of select drugs generated 109.5 million net sales in 2019, mostly contributed by cardiovascular drug Ebrantil, one of the products sold to Hasten. As per the contract, the employees who are dedicated to the commercial support of these products will also be transferred to Hasten. As for the manufacturing and supply agreement, Takeda will continue to manufacture and supply the divested products to Hasten. The agreement is estimated to close by June 30, 2021, and until then, Takeda will have the full right of these products. For future use of proceeds, Takeda will firstly reduce its debt and then facilitate the R&D and expand its manufacturing capacity of these five core business areas. “This announcement marks continued progress on our commitment to simplify our global portfolio and remain focused on investing in our growth drivers, and research and development pipeline,” said Costa Saroukos, Chief Financial Officer, Takeda. “We remain committed to expansion in China with more than 15 planned approvals over the next five years. By continuing to execute and deliver on Takeda’s financial commitments, including paying down debt and focusing on our highly innovative portfolio, we can sustain our long-term growth and continue to deliver life-transforming treatments for patients worldwide.” For the past two years, Takeda has exceeded its $10 billion non-core asset divestiture target. Here are some of the divestiture agreements in 2020. March 2: Sold 30 prescription pharmaceuticals and over-the-counter (OTC) products in Near East, Middle East, and African countries within its Growth and Emerging Markets Business Unit (GEM BU) to Acino for 200 million March 2: Sold 18 select OTC and prescription pharmaceutical assets in Brazil, Mexico, Argentina, Colombia, Ecuador, Panama, and Peru to Hypera Pharma for 825 million March 4: Sold 20 OTC and prescription pharmaceutical products exclusively in Russia, Georgia, and several countries from within the Commonwealth of Independent States to STADA Arzneimittel AG for 660 million. April 24: Sold 110 select OTC and prescription pharmaceutical assets in Europe to Orifarm for 670 million September 8: Sold non-core prescription pharmaceutical products sold predominantly in Europe and Canada to Cheplapharm for 562 million. December 1: Sold 18 pharmaceutical products and OTC products in the Asia Pacific to Celltrion for 278 million.

Acquisition

100 Deals associated with Candesartan Cilexetil

External Link

KEGG	Wiki	ATC	Drug Bank
D00626	Candesartan Cilexetil	C09CA06	DB00796

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Parenchymal renal hypertension	JP	Takeda Pharmaceutical Co., Ltd.	12 Mar 1999
Heart Failure	AU	AstraZeneca Pty Ltd.	29 Jul 1998
Left ventricular systolic dysfunction	AU	AstraZeneca Pty Ltd.	29 Jul 1998
Hypertension	US	ANI Pharmaceuticals, Inc.	04 Jun 1998
Essential Hypertension	GB	-	29 Apr 1997

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Aortic Valve Disease	Phase 3	FI	AstraZeneca PLC	01 May 2009
Aortic Valve Stenosis	Phase 3	FI	AstraZeneca PLC	01 May 2009
Migraine With Aura	Phase 3	NO	AstraZeneca PLC	01 Apr 2009
Migraine Without Aura	Phase 3	NO	AstraZeneca PLC	01 Apr 2009
Diabetes Mellitus	Phase 3	DE	Takeda Pharmaceutical Co., Ltd.	01 Jan 2008
Functional disorder	Phase 3	DE	Takeda Pharmaceutical Co., Ltd.	01 Jan 2008
Cardiotoxicity	Phase 3	NL	AstraZeneca PLC	01 Jun 2007
HER2 Positive Breast Cancer	Phase 3	NL	AstraZeneca PLC	01 Jun 2007
Chronic heart failure	Phase 3	-	Takeda Pharmaceutical Co., Ltd.	01 Dec 2005
Stroke	Phase 3	NO	Takeda Pharmaceutical Co., Ltd.	01 Jun 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03640312 (QUARTET USA, Pubmed \| Hypertens Res) Manual	Phase 2	Hypertension Add-on	62	candesartanandesartan 2 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg)	kzmsqgyvrc(zvxrkipapq) = wkybbwrcmi ptyxaqkkgy (oacvgpxlrn ) View more	Positive	08 Apr 2024
				candesartan 8 mgcandesartan 8 mg	-
NCT04138316 (CandeSpartan, Pubmed \| Cephalalgia) Manual	Not Applicable	Migraine Disorders	86	Candesartan	ufklxkheio(swjwjuftch) = yoiasnhjrf dhhscxvxoo (vpnddrrofw ) View more	Positive	01 Apr 2024
NCT02646982 (CEDAR, CTgov)	Phase 2	Alzheimer Disease \| Mild cognitive disorder	77	Candesartan (Candesartan)	mainfwqqsj(aikavnrrfd) = jdjzneepod wbampsetml (xqyxzhwoba, qarguesdar - wfvdlpntiy) View more	-	29 Sep 2022
				Placebo (Placebo)	mainfwqqsj(aikavnrrfd) = rwdmzmpzvt wbampsetml (xqyxzhwoba, xemshfmfln - nwntkobsye) View more
EUCTR2016-000679-25-ES (MDS2022)	Phase 2	Cognitive Dysfunction \| Parkinson Disease α-synuclein deposition	36	Candesartan 4mg-8mg-4mg	ifuvdjwhtu(mtdvasyiyw) = Adverse events were mild with no serious events related to candesartan and with no worsening of motor or behavioral status opflbsqowa (khqfmimvsw )	Negative	15 Sep 2022
				Placebo
NCT02646982 (Pubmed \| Brain Commun)	Phase 2	Alzheimer Disease	77	Candesartan	fkkhhowxig(kebgxxmlfa) = mgbtrkojak mhodsvzmcl (tknofrqicw, 313.27 - 2110.63) View more	-	01 Jan 2022
NCT01678794 (CTgov)	Phase 1/2	Cardio-Renal Syndrome	33	Candesartan (Candesartan)	hlyzshuvlm(kvmwdfeorj) = lsilsuvavy olvldbdfvm (bbhavcdxfx, bbryuiltsa - khvgqlukmz) View more	-	18 Nov 2021
				Placebo (Placebo)	hlyzshuvlm(kvmwdfeorj) = wwrancrhyl olvldbdfvm (bbhavcdxfx, jtrbuqnbij - oaqirxysql) View more
NCT01434134 (PRADA, Pubmed \| Circulation)	Phase 2	Breast Cancer Adjuvant	120	Candesartan cilexetil	bygypxzgje(vakzcpzcxk) = wykazgjvab bksixwpkgw (gthjumdrep, 0.5 - 2.8)	-	16 May 2021
				Metoprolol succinate	bygypxzgje(vakzcpzcxk) = gdgjxehvgo bksixwpkgw (gthjumdrep, 0.4 - 2.7)
NCT01984164 (CALIBREX, CTgov)	Phase 2	Mild cognitive disorder \| Hypertension	176	Candesartan (Candesartan)	kpelihiqmf(krqargekwg) = sgvtcganxc yewrmneauu (meyofadywk, lvdvtlbhoj - spxioxtoda) View more	-	21 Feb 2021
				Lisinopril (Lisinopril)	kpelihiqmf(krqargekwg) = jshqkzyshx yewrmneauu (meyofadywk, loxefwexqe - ofmqsvnepv) View more
CALIBREX (AAIC2020)	Not Applicable	Mild cognitive disorder	176	Candesartan	zxfzanejkj(qsxajfnxni) = mjtinrrsgg pthucqtwiy (aomxpebihw ) View more	Positive	07 Dec 2020
				Lisinopril	zxfzanejkj(qsxajfnxni) = ougzvstgmu pthucqtwiy (aomxpebihw ) View more
NCT01984164 (Pubmed \| JAMA Netw Open)	Phase 2	Mild cognitive disorder	176	Candesartan	elrutiiclt(hibdichpdu): ES = -12.8 (95% CI, -22.5 to -3.1) View more	-	03 Aug 2020
				Lisinopril

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis